The 6 most recent market catalysts affecting $MNPR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $145
Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Monopar Therapeutics (MNPR) and raised the price target from $128 to $145. This action signals continued conf…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Monopar Therapeutics and raised the price target from $125 to $128. This action indicates a continued positive se…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
BTIG analyst Jeet Mukherjee has maintained a 'Buy' rating on Monopar Therapeutics (MNPR) and raised the price target from $117 to $133. This action signals a positive outlook from …
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Monopar Therapeutics Q2 EPS $(0.62) Misses $(0.56) Estimate
Monopar Therapeutics (MNPR) disclosed a Q2 EPS loss of $(0.62), which not only missed the consensus estimate of $(0.56) by a notable 10.71% but also marked a significant 77.14% inc…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125
HC Wainwright & Co. analyst Andres Y. Maldonado has maintained a 'Buy' rating on Monopar Therapeutics (MNPR) and raised the price target from $105 to $125. This action indicates in…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 75
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
Monopar Therapeutics has begun the rolling submission of its New Drug Application (NDA) for ALXN1840, a drug targeting Wilson disease. This is a significant step towards potential …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.